Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
15h
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical ...
Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth —— $457 million net income, driven by ...
Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth - - $457 million net income, driven by profitable core operations and non-core disposal - - Rapidly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results